Gerresheimer | Special Situation In A Glass Vial
A Market Leader Supplying Mission Critical Products In Oversold Territory
DISCLAIMER & DISCLOSURE: The author has no position in Gerresheimer at the time of publication, but that may change. The views expressed are those of the author at the time of publication and may change without notice. The author has no duty or obligation to update this information. Some content is sourced from third parties believed to be reliable, but accuracy is not guaranteed. Forward-looking statements involve assumptions, risks, and uncertainties, meaning actual outcomes may differ from those envisaged in this analysis. Past performance is not indicative of future results. All investments carry risk, including financial loss. This analysis is for educational purposes only and does not constitute investment advice or recommendations of any kind. Conduct your own research and seek professional advice before investing.
Why Should I Care About Gerresheimer?
Gerresheimer AG (Germany: GXIG), which also trades as US ADR (OTCPK: GRRM.Y) is a case study in how a strong industrial franchise can lose investor confidence quickly. While this is disappointing for existing shareholders, it creates an interesting special situation play.
The Düsseldorf-based company operates as a leading player at the critical interface between healthcare and manufacturing, producing the specialty glass and plastic containers that make modern medicine possible. Its vials, ampoules and injector pens are used in the delivery of vaccines, insulin and GLP‑1 weight-loss drugs such as Ozempic, and the company supplies both key players in the GLP-1 market: Novo Nordisk and Eli Lilly.
The segments of Gerresheimer are:
To put things in perspective, Gerresheimer was the world’s largest manufacturer of vaccine glass vials during the Covid pandemic, highlighting its dominant role in this segment.
The pharmaceutical packaging market is projected to grow robustly, reaching an estimated $356.7 billion globally by 2034, driven by aging populations, rising chronic diseases and advancements in biologics and smart packaging technologies.
Within this expansive market, Gerresheimer is focused on higher-margin, technologically advanced niches like drug delivery systems for biologics and autoinjectors, distinguishing it from more commodity-like packaging suppliers.
However, once celebrated as a pandemic-era champion, the company has hit some turbulence. After a chain of self-inflicted setbacks and unlucky events, it now faces the arduous task of rebuilding credibility, profitability and growth momentum.
What happened? Could this be an interesting entry opportunity?
The ‘Formula G’ Strategic Plan
Gerresheimer’s pedigree runs deep. During the pandemic, its glass manufacturing business supplied roughly 3.5 billion vaccine vials globally, making it the world leader by volume and a de‑facto partner to nearly every major vaccine producer.
That boom, however, proved ephemeral. As vaccination programs normalized, the tailwind evaporated, leaving behind excess capacity and a newly acquired plastics and devices division struggling to meet expectations.
What was once a defensive, high-demand business shifted into something cyclical almost overnight, and the stock began a long decline that wiped away over 70% of its value.
Still, the company remained indispensable to the medical supply chain. Gerresheimer’s injection pen segment (crucial for Novo Nordisk’s Ozempic and Wegovy) has become a structural growth engine, responsible for an increasing share of group revenue and forming part of its “High Value Solutions” strategy.
Under the “Formula G” growth plan, Gerresheimer invested heavily, hundreds of millions of euros, into expanding its manufacturing capabilities, particularly focusing on biologics and injectables. Key plants in Mexico, North Macedonia, Germany, and the United States were upgraded to meet the growing demand for GLP-1 therapeutics and other complex drug formats. This investment marked a significant step toward enhancing the company’s position in the evolving pharmaceutical landscape.
In 2024, Gerresheimer further accelerated its transformation by acquiring Bormioli Pharma. This merger aimed to bolster Gerresheimer’s evolution into a fully integrated systems and solutions provider. Bormioli Pharma, known for its diverse range of pharmaceutical primary packaging made from glass and plastic, as well as its closures, accessories, and dosing systems, brought substantial value. The acquisition expanded Gerresheimer’s product offering, enabling it to provide a more comprehensive suite of integrated solutions. Additionally, Bormioli Pharma’s nine production sites across Europe, particularly in Southern Europe, enhanced Gerresheimer’s manufacturing capacity, solidifying its position as a leading full-service provider.
Bormioli Pharma’s track record of double-digit profitable growth and healthy margins was expected to positively impact Gerresheimer’s Adjusted EBITDA and Adjusted EPS from the outset, thanks to anticipated synergies. In fact, Bormioli Pharma delivered an impressive 15.7% revenue growth in the first half of 2025, factoring in the M&A effects. However, early 2025 brought unexpected challenges. Post-acquisition organic growth in both revenue and EBITDA was slower than anticipated, raising internal concerns about the price paid for the acquisition, the performance of the newly acquired assets and the difficulty of realizing the projected synergies, especially in the moulded glass segment.
The combined moulded glass operations created what Gerresheimer initially referred to as the “Moulded Glass Powerhouse.” This new entity was strategically reviewed for growth prospects and competitiveness, a move that was initially well-received by analysts. Many expected that the review would clarify the direction of the business and reassure the market, particularly as some investors had previously considered the moulded glass operations to be a “value dilutive” part of Gerresheimer’s portfolio.
The surge in capital expenditure pushed Gerresheimer’s free cash flow into negative territory, a situation that some analysts argued should be viewed as “short-term pain for long-term gain.” The company’s investments in expanding its technical capabilities were seen as necessary for future growth, rather than an operational misstep. However, despite the initial optimism surrounding this strategy, things quickly became more complex.
Following the merger, concerns from activist investors and some former executives began to surface. The price Gerresheimer paid for Bormioli Pharma, around €800 million in enterprise value, was perceived by some as overly generous. The acquisition led to a significant increase in Gerresheimer’s debt, and subsequent profit warnings, partly attributed to weaker demand in the cosmetics and oral liquids markets, caused the company’s stock to tumble to multi-year lows.
As a result, shareholders and activist groups called for changes in leadership and for a divestment from the Moulded Glass business to reduce debt and unlock shareholder value.
Green Shoots of Recovery & The Strategy Pivot
By October 2025, after seven years at the helm, CEO Dietmar Siemssen stepped down “by mutual agreement” due to the mounting challenges. His departure marked a pivotal moment for Gerresheimer, with Uwe Röhrhoff appointed as interim CEO. Röhrhoff, who had previously served as the company’s CEO from 2010 to 2017, returned to guide Gerresheimer through this transitional phase.
Despite the setbacks, there are encouraging signs of recovery and a turnaround.
The acquisition of Bormioli Pharma significantly broadened Gerresheimer’s reach, and its focus on biologics and injectables continues to accelerate.
The company’s established relationships with leading drug manufacturers provide a degree of revenue stability that many mid-cap competitors can only aspire to.
The key strategic question moving forward is whether Gerresheimer can simplify its portfolio and restore operational discipline.
Gerresheimer announced the decision to separate and subsequently initiate a sales process for its Moulded Glass business in August 2025. This legacy business, which once produced billions of vaccine vials, now poses a drag on performance. The moulded glass division serves diverse end markets (pharma, cosmetics, food & beverage) and is seen as a better fit for a new, independent owner who can focus specifically on these markets.
Divesting this division aligns with Gerresheimer’s strategy to become a “pure-play” provider of pharmaceutical and biotech systems, shedding its lower-margin past while simultaneously reducing the debt incurred from the Bormioli acquisition.
The “Moulded Glass Powerhouse” is a global leader, comprising eight production sites across Europe (including Germany, Belgium, Italy), the US, and India, and having generated pro forma revenues of approximately €735 million in 2024. Its sale would clear most, if not all of Gerresheimer’s long term debt.
The separation of the businesses is underway, and the sale is expected in FY2026.
With all of the negative news already priced in, any progress in executing this strategy could trigger a sharp rally in Gerresheimer’s stock.
Despite the turbulence, the long-term outlook for Gerresheimer remains solid. The company occupies a unique position at the intersection of pharmaceutical innovation and manufacturing transparency. Its operational advantages, including technical certification, client integration, and regulatory trust, create a competitive moat that is not easily replicated by other companies in the industry. As such, Gerresheimer’s core strengths continue to provide a strong foundation for future growth, even amidst the challenges of the present.
Oral GLP-1s and the future of Injectables
Novo Nordisk is aggressively developing oral Amycretin, a pill that early data suggests could be more effective than injectable Wegovy.
Phase 3 trials of Amycretin are due to occur in 2026 and, if successful, a commercial launch could occur around 2028–2029.
The risk to Gerresheimer is clear to see, and short-sellers have played on this narrative by arguing that the “injection pen super-cycle” may be shorter than the market previously hoped.
However, Gerresheimer has vigorously defended the pen business, arguing that Oral GLP-1s are notoriously inefficient. The body destroys most of the drug before it works, meaning a pill requires roughly 100x the amount of active ingredient compared to an injection to achieve the same effect. Not only does this make the oral variation far more expensive for users, manufacturing enough GLP-1 to meet demand is currently the industry’s biggest bottleneck, so efficacy or the delivery mechanism is key. This means injectables will almost certainly remain the delivery mechanism of choice for the foreseeable future.
The other factor to consider is that global demand for GLP-1 medications is increasing rapidly and so this is not a zero-sum game. It is not a question of the oral variety displacing injectables, it is more a question of each taking a share of a rapidly growing pie. Both varieties have plenty of scope to grow. It is also worthy of note that Gerresheimer manufactures plastic packaging for solid dosages (pill bottles), although these are low-margin, commoditized plastic products compared to high-precision medical devices like auto-injectors.
Returning our focus to the injectable variants of the GLP-1s, consider the regulatory angle. When a medication is approved by the FDA, or equivalent elsewhere in the world, the delivery process is written into the approval. Gerresheimer is documented in the filings for these drugs, making them almost impossible for Pharms companies to displace for the current generation of medicines. Doing so would require re-applying for FDA approval, which no pharma company will be willing to do. They are entirely focused on attaining regulatory approvals for the next wave of drugs. This makes Gerresheimer’s products mission critical.
It should also be noted that Gerresheimer supplies both Eli Lilly and Novo Nordisk, evidence that Gerresheimer is not reliant on a single customer for its growth in the most important sector of its business. It also validates Gerresheimer’s technology and manufacturing scale as being essential to both market leaders. Gerresheimer’s massive capital expenditure, including the construction of the new US facility in Peachtree, Georgia, is specifically designed to meet the soaring demand for autoinjectors from both Novo Nordisk and Eli Lilly. This confirms that both companies are pulling volume from Gerresheimer and that it is necessary for the pharmaceutical giants to realize their blockbuster drug revenues.
Then there’s the acquisition of Catalent by Novo Holdings (the parent of Novo Nordisk) which closed in late 2024, involving Novo Nordisk acquiring three key Catalent fill-finish sites (in Italy, Belgium, and the US). The acquired sites are specialized in sterile injectable filling, not oral solid dosage (pill) manufacturing. This reinforces the view that Novo Nordisk’s near-term focus is maximizing the current highly profitable injectable portfolio.
This is relevant because the three acquired sites specialize in fill-finish operations, the process of putting the drug substance into the sterile injection pens and packaging them. Catalent was already a key contractor for Novo Nordisk for this service. This action signals that Novo Nordisk is deeply committed to scaling injection pen production for the foreseeable future. This move is reassuring for Gerresheimer in the short to medium term. It confirms that the bottleneck is filling/packaging (Catalent’s job), not the pen device manufacturing (Gerresheimer’s job). Novo Nordisk cannot fill a pen that hasn’t been made, so this acquisition increases the pressure on Gerresheimer to deliver high volumes of empty pens and cartridges to be filled at the newly acquired Catalent sites.
Finally, before wrapping up this section, there’s something else to be discussed. In late 2023, Ypsomed, a major Swiss medical device manufacturer, secured a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. To accelerate production, Novo Nordisk is directly contributing a “significant part” of the investment for Ypsomed’s new manufacturing infrastructure. This shows Novo Nordisk is proactively financing its supply diversification.
The Ypsomed contract creates both a headwind and a reassurance for Gerresheimer. Novo Nordisk may be bringing in a competitor to reduce its dependency on any single supplier for its high-growth product pipeline. While this may initally appear problematic for Gerresheimer, the fact that Novo Nordisk is investing billions and signing up two major injectable device suppliers for its GLP-1 pens confirms the enormous scale of current and projected demand. Said differently, Novo Nordisk is clearly not thinking about replacing injectables with orally delivered medications anytime soon. The oral variants should be viewed as supplementary at best.
Gerresheimer was initially seen as the leading supplier for CagriSema, having developed a specialized dual-chamber syringe for this combination drug. Ypsomed’s YpsoMate 1mL autoinjector is a simpler device for a single-chamber formulation of a successor drug. Gerresheimer’s ability to handle highly complex, customized delivery systems remains a significant competitive advantage that Ypsomed may not yet fully replicate, so Novo Nordisk may have specific use cases for each company.
In the short-term, this oral GLP-1s represent little or no threat to Gerresheimer. The ultimate impact of the oral drug landscape remains a five-year horizon risk. To mitigate any medium-term threat, it is actively seeking to unlock shareholder value and pivot its long-term strategy.
The company is leaning heavily into its Biologics portfolio (vials and syringes for complex, non-GLP-1 drugs) and, as noted earlier, is progressing with the separation and potential sale of its lower-growth Moulded Glass division.
Valuation and the Failed Takeover
In early 2025, a consortium led by private‑equity groups KKR and Warburg Pincus approached Gerresheimer with an offer of nearly €90 per share, which placed the company’s valuation around €3 billion.
The board entertained the takeover talks but no agreement was reached. The parties failed to align on valuation and strategic interests. KKR walked away from the deal in April 2025, citing uncertainties and strategic misalignments. Warburg Pincus stayed in talks longer but decided to exit in June 2025 as the share price dropped to about €50, causing it to rethink its €90 bid.
That was only 10 months ago and the share price today is a mere €25: the company is now capitalized at less than half its top line revenue which looks interesting given a mid-cycle operating margin of ~10.5%.
Shareholders were disappointed at the failure of the takeover. However, the undeniable truth is that two very well respected buyers did their due diligence and believed that the company was worth €90 per share. It is difficult to believe that they would both have been out by a factor of 3x on those calculations. The dissolution of talks leaves open the possibility of renewed private equity interest in the future, albeit likely at a lower price, but significantly more than where the stock trades today.
Macro- and Micro-Economic Turbulence
Not only were shareholders disappointed by the collapse of the takeover, but a series of profit warnings and production delays, compounded by the flooding of its Morganton plant during Hurricane Helene, eroded faith in Gerresheimer’s management execution still further.
This culminated in the CFO, Bernd Metzner, resigning suddenly in August 2025.
The optics worsened further as, a short time later, Germany’s financial regulator BaFin announced a formal audit into possible accounting irregularities in Gerresheimer’s 2024 consolidated financial statements. The suspicion surrounded the early recognition of revenue under certain “bill‑and‑hold” arrangements - transactions recorded before physical delivery to customers. Though Gerresheimer denied wrongdoing and pledged cooperation, the stock plunged over 35% on the day the probe became public.
The timing raised eyebrows across Frankfurt. Some market participants speculated that the investigation may have been triggered by findings unearthed during private‑equity due diligence, raising the possibility of a coordinated leak designed to compress the valuation and reopen acquisition discussions from a lower base.
Whether that theory holds or not, the share price collapse has left Gerresheimer trading at distressed multiples for a company still fundamentally embedded in the global healthcare supply chain.
Financially, 2025 has been tough. The company has cut full‑year guidance three times. Organic revenue is now expected to decline 2% to 4%, with an adjusted EBITDA margin of 18.5% to 19%, below the 20% level once promised to investors .
Subdued demand in cosmetics packaging and containment for oral liquids weighed on volumes, while inflation and ramp‑up inefficiencies in new plants hurt profitability.
While the BaFin probe introduces undeniable risk, its scope appears narrow and largely procedural rather than existential. The new CFO, Wolf Lehmann, formerly of private equity firm Triton, brings discipline and a new perspective may accelerate efforts to regain control over capital allocation and financial reporting. Should he succeed, Gerresheimer could emerge leaner, steadier and better positioned in booming biologics and GLP‑1‑related markets.
Competition
Gerresheimer is a market leader, but key competitors include:
Catalent Inc. — A major player in drug delivery technologies and clinical supply solutions.
SCHOTT AG — German-based glass manufacturer specializing in pharma glass packaging.
Nipro Corporation — Japanese supplier of medical devices and glass containers.
Becton Dickinson (BD) — Known for injectable drug delivery systems.
SiO2 Materials Science — Innovator in advanced glass coatings and pharmaceutical packaging.
Many of these competitors focus on biotech drug delivery innovation or glass pharmaceutical packaging, directly overlapping with Gerresheimer’s core capabilities. However, Gerresheimer’s integrated portfolio (combining glass, plastics, and device manufacturing) gives it an advantage in offering turnkey solutions to pharmaceutical clients.
The Counter Argument
Morpheus Research (a short seller) has recently published its bear thesis on Gerresheimer, which sets out a strong counter-argument to the turnaround narrative.
Morpheus focuses heavily on the threat of oral GLP-1s and the shift to simpler, commoditized single-chamber syringes for next-generation GLP-1s, where Gerresheimer has no exclusivity and faces intense competition. Both of these issues have been discussed in detail earlier, so there is no need to revisit those again here.
Morpheus focuses on the Bormioli Pharma acquisition, the price paid (which it considers excessive) and the resulting levels of debt assumed by Gerresheimer. Again, this has been discussed above. But Morpheus goes on to claim that Gerresheimer’s former CEO was simultaneously working for a portfolio company of Triton Partners, the private equity firm that sold Bormioli, suggesting a possible conflict of interest. Morpheus also alleges that the Bormioli manufacturing assets were old and required significant deferred CAPEX. It points to the Chicago Heights factory, which it describes as an unattractive, low-growth asset. It states that this poor acquisition is now severely hampering the planned divestiture of the Moulded Glass division, and that a sale is unlikely to materialize at a price high enough to meaningfully deleverage the company.
Finally, Morpheus argues that Gerresheimer has employed a series of aggressive accounting tactics to artificially inflate key financial metrics, such as Adjusted EBITDA and operating income. These practices include capitalizing development costs over decades (as long as 34 years) to immediately boost operating income, extending the useful life of assets, and capitalizing borrowing costs. The report suggests this “financial engineering” artificially propped up earnings before the formal BaFin investigation into accounting irregularities became public.
In short, Morpheus Research’s position is that the company’s valuation is too high given the severe, underappreciated risks to its core growth driver, its unsustainable debt, its broken M&A strategy, and its reliance on aggressive financial reporting.
Are these counter arguments over-done? The following is an excerpt from the Morpheus Research short-seller disclaimer:
“You should assume that as of the publication date of any short-biased report or letter, Morpheus Research… has a position… and, therefore, stands to realize significant gains if the price of the securities move.”
When it describes its own work as a “short-biased report”, perhaps we could assume that it is, to a great or lesser extent, talking its own book (trying to profit by influencing the sentiment of the market).
Short reports can be valuable in surfacing hidden problems and sharpening the questions investors should be asking. But while they often allow the author to reap a windfall as a short seller (Gerresheimer, for example, is down more than 80% from its peak), they can also push sentiment too far in the opposite direction, creating compelling entry points for long-only investors.
Is Gerresheimer a Good Investment?
To sum up, Gerresheimer is a turnaround candidate wrapped in controversy. It combines near‑term governance overhangs with long‑term structural relevance. For investors with the patience to endure another few quarters of uncertainty, the reward could prove asymmetric: a business burdened by mistrust but supported by enduring demand and technical edge. It ultimately turns on whether management can regain control of the story and whether the market’s extreme pessimism has finally gone too far.
What do you think? Please post your comments below.
Fantastic deep dive on the regulatory moat angle here. The Catalent acquisition piece is actually the strongest signal - Novo doubling down on fill-finish capacity for injectables means they're betting big on device throughput, not replacing the delivery mechanism. Most people miss that the bottleneck shifted downstream not upstream. The 100x dosing inefficiency on oral GLP-1s is brutal economics that doesnt get enough attenton and basically locks in injectables for the next cycle regardless of whats in the pipeline.
Hallo James. Thanks for this write up. I'm considering Gerresheimer as a potential turnaround, but I'm not in a hurry. I will wait maybe a quarter or two. An investor day where they share their vision would really help. I see better options (at least in my view) out there right now.
PS.: talking about european companies, check out Teamviewer. This could be really interesting in comming quarters